RAREUltragenyx Pharmaceutical Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 20785
Ticker: RARE
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2014-01-31
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: RARE

Detail

Enriched 2026-08-14 20:47

Market cap: $2,648,097,128.78
Shares outstanding (class): 98,588,873
Shares outstanding (weighted): 98,588,873
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 1,371
Location: NOVATO, CA
Homepage: https://www.ultragenyx.com
Description: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Market cap and share counts drift.

Funds holding this security

140 funds · 141 positions · $381.81M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$65.11M	0.88%	3,107,837 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$61.50M	0.00%	2,935,570 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$44.31M	0.03%	2,114,864 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$24.92M	0.06%	1,189,629 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$22.62M	0.03%	1,079,869 NS	FIGI
AQR Long-Short Equity Fund AQR Funds	—	$17.00M	0.21%	811,441 NS	FIGI
VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS	—	$16.40M	0.16%	782,649 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$14.25M	0.18%	680,286 NS	FIGI
Touchstone Funds Group Trust-Touchstone Sands C… Touchstone Funds Group Trust	—	$13.63M	0.71%	650,491 NS	FIGI
iShares Russell Mid-Cap Growth ETF iShares Trust	IWP	$12.95M	0.07%	618,129 NS	FIGI
iShares Russell 1000 Growth ETF iShares Trust	IWF	$7.95M	0.01%	379,627 NS	FIGI
iShares Russell Mid-Cap ETF iShares Trust	IWR	$7.37M	0.02%	351,786 NS	FIGI
AQR Managed Futures Strategy Fund AQR Funds	—	$5.12M	0.17%	244,513 NS	FIGI
College Retirement Equities Fund - Total Global… College Retirement Equities Fund	—	$5.01M	0.00%	239,290 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$4.96M	0.20%	236,751 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERRARE
FIGI_COMPOSITEBBG001RWPDW6
FIGI_SHARE_CLASSBBG001V2MJJ2
CIK0001515673
ISINUS90400D1081
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Ultragenyx is a biopharmaceutical company developing treatments for rare diseases, classified under pharmaceuticals.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.